A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors-MedSci.cn

A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors

Drilon, A; Nagasubramanian, R; Blake, JF; Ku, N; Tuch, BB; Ebata, K; Smith, S; Lauriault, V; Kolakowski, GR; Brandhuber, BJ; Larsen, PD; Bouhana, KS; Winski, SL; Hamor, R; Wu, WI; Parker, A; Morales, TH; Sullivan, FX; DeWolf, WE; Wollenberg, LA; Gord

Rothenberg, M (reprint author), Loxo Oncol Inc, 281 Tresser Blvd,9th Floor, Stamford, CT 06901 USA.; Hyman, DM (reprint author), Mem Sloan Kettering Canc Ctr, 300 E 66th St,Room 1353, New York, NY 10065 USA.

Abstract

Larotrectinib, a selective TRK tyrosine kinase inhibitor (TKI), has demonstrated histology-agnostic efficacy in patients with TRK fusion-positive canc......

Full Text Link

Links

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors

科室

工具

服务